Verzögert
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
93.2 USD | +1.71% | -2.19% | -4.09% |
21.05. | Banken drücken australische Aktien nach unten; James Hardie fällt auf 5-Monats-Tief | RE |
17.05. | Australische Aktien geben nach, da Banken, Technologie- und Gesundheitswerte nachgeben | RE |
Kurzporträt
Mitarbeiterzahl: 32 065
Umsatz nach Geschäftsbereich
AUD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
CSL Behring
69,8
%
| 11 857 | 81,4 % | 13 811 | 69,8 % | +16.48% |
CSL Seqirus
15,3
%
| 2 708 | 18,6 % | 3 019 | 15,3 % | +11.52% |
CSL Vifor
14,9
%
| - | - | 2 957 | 14,9 % | - |
Umsatz je Region
AUD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
United States
49,3
%
| 7 065 | 48,5 % | 9 757 | 49,3 % | +38.10% |
Rest of World
21,4
%
| 2 776 | 19,1 % | 4 236 | 21,4 % | +52.59% |
Australia
7,9
%
| 1 409 | 9,7 % | 1 554 | 7,9 % | +10.23% |
Germany
6,5
%
| 1 077 | 7,4 % | 1 292 | 6,5 % | +19.93% |
China
5,9
%
| 1 027 | 7,0 % | 1 158 | 5,9 % | +12.79% |
United Kingdom
5,4
%
| 822 | 5,6 % | 1 066 | 5,4 % | +29.68% |
Switzerland
3,7
%
| 388 | 2,7 % | 725 | 3,7 % | +86.90% |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Paul McKenzie
CEO | Chief Executive Officer | 58 | 01.06.19 |
Director of Finance/CFO | 59 | 01.10.20 | |
Mark Hill
CTO | Chief Tech/Sci/R&D Officer | 62 | 01.10.20 |
Chief Tech/Sci/R&D Officer | 66 | 01.10.18 | |
Andrew Nash
CTO | Chief Tech/Sci/R&D Officer | - | 01.11.06 |
Director/Board Member | 70 | 01.03.97 | |
Mark Dehring
IRC | Investor Relations Contact | - | - |
Kate Priestman
PRN | Corporate Officer/Principal | - | 11.09.23 |
Ken Lim
PRN | Corporate Officer/Principal | 50 | 01.01.13 |
Bill Campbell
PRN | Corporate Officer/Principal | 64 | 01.01.14 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Carolyn Hewson
BRD | Director/Board Member | 69 | 09.12.19 |
Brian McNamee
PSD | President | 68 | 01.07.90 |
Alison Watkins
BRD | Director/Board Member | 61 | 19.08.21 |
Director/Board Member | 70 | 01.03.97 | |
Megan Clark
BRD | Director/Board Member | 66 | 16.02.16 |
Marie McDonald
BRD | Director/Board Member | 68 | 14.08.13 |
Sam Lewis
BRD | Director/Board Member | - | 01.01. |
Duncan Maskell
BRD | Director/Board Member | 63 | 18.08.21 |
Paul McKenzie
CEO | Chief Executive Officer | 58 | 01.06.19 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 483 093 257 | 480 846 726 ( 99,53 %) | 0 | 99,53 % |
Unternehmensbesitz
Name | Aktien | % | Bewertung |
---|---|---|---|
CARA THERAPEUTICS, INC. 13,53% | 7 396 770 | 13,53% | 5 177 739 $ |
Unternehmenskontakt
Konzerngesellschaften
Name | Kategorie und Branche |
---|---|
CSL Behring Lengnau AG
| |
CSL Behring GmbH
CSL Behring GmbH Pharmaceuticals: MajorHealth Technology Part of CSL Ltd., CSL Behring GmbH is a German company that actively collaborates to develop special programs and activities for patients with rare diseases. The company is based in Marburg, Germany. The CEOs of the company are Lutz Guenter Bonacker, Michael Schröder, Craig Shelanskey. |
Pharmaceuticals: Major
|
CSL Behring UK Ltd.
CSL Behring UK Ltd. Pharmaceuticals: MajorHealth Technology Part of CSL Ltd., CSL Behring UK Ltd. is a company that manufactures and supplies plasma therapies. The company is based in Haywards Heath, UK. The British company was founded in 1916 by Emil von Behring. |
Pharmaceuticals: Major
|
CSL Plasma GmbH
CSL Plasma GmbH Medical/Nursing ServicesHealth Services CSL Plasma GmbH provides plasma collection and donation services. It specializes in the collection, testing, and management of plasma taken from blood donors. It focuses on the use of plasma as a key ingredient for products crucial to treating patients suffering from hemophilia, shock or trauma, immune deficiencies, and other blood disorders. It operates through its testing laboratories, collection facilities, and logistics centers. The company is headquartered in Marburg, Germany. |
Medical/Nursing Services
|
CSL Finance GmbH
CSL Finance GmbH Financial ConglomeratesFinance Part of CSL Ltd., CSL Finance GmbH is a German company that provides investment services. The company is based in Marburg, Germany. The CEOs are Antje Michel, Dieter Engstfeld, John Andrew Goodman Levy. The company was founded in 2014. |
Financial Conglomerates
|
CSL Behring Recombinant Facility AG
CSL Behring Recombinant Facility AG BiotechnologyHealth Technology Part of CSL Ltd., CSL Behring Recombinant Facility AG is a Swiss biotherapeutics company that develops and delivers innovative therapies to improve patients' lives. The company is based in Bern, Switzerland and has a manufacturing site there. The company's portfolio includes a wide range of recombinant and plasma-derived products. |
Biotechnology
|
CSL Behring LLC
CSL Behring LLC BiotechnologyHealth Technology CSL Behring LLC researches, develops, manufactures, and markets biotherapies that are used to treat serious and rare conditions. It offers protein-based therapies in the areas of Bleeding Disorders, Fluid Replacement, Hereditary Angioedema, Immunoglobulin, Pulmonary, and Wound Healing Therapies. The company was founded in 2004 and is headquartered in King of Prussia, PA. |
Biotechnology
|
CSL Behring AG
CSL Behring AG BiotechnologyHealth Technology Part of CSL Ltd., CSL Behring AG is a Swiss company that develops biological products. The company is based in Bern, Switzerland. |
Biotechnology
|
CSL Behring Beteiligungs- und Verwaltungs GmbH & Co. KG
CSL Behring Beteiligungs- und Verwaltungs GmbH & Co. KG Pharmaceuticals: MajorHealth Technology Part of CSL Ltd., CSL Behring Beteiligungs- und Verwaltungs GmbH & Co. KG is a German pharmaceutical company that manufactures pharmaceutical products. The company is based in Marburg, Germany. The company was founded in 2004. The CEO is Craig Shelanskey. |
Pharmaceuticals: Major
|
Sektor
Umsatz nach Geschäftsbereich
Umsatz je Region
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+2.24% | 40.49 Mrd. | |
-15.00% | 32.79 Mrd. | |
+63.56% | 26.23 Mrd. | |
-21.94% | 14.52 Mrd. | |
-7.63% | 13.09 Mrd. | |
-42.60% | 11.6 Mrd. | |
-12.64% | 11.5 Mrd. | |
+5.02% | 8.82 Mrd. | |
-13.45% | 7.92 Mrd. |
- Börse
- Aktien
- 890952 Aktie
- A115DF Aktie
- Unternehmen CSL Limited